Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade

A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer

(2019) Lucia D’Amico et al.   Journal for ImmunoTherapy of Cancer

Anthracycline-based consolidation may determine outcome of post-consolidation immunotherapy in AML

(2019) Johan Aurelius et al.   LEUKEMIA & LYMPHOMA

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

(2019) Leonie Voorwerk et al.   NATURE MEDICINE

Tumor lysis with LTX-401 creates anticancer immunity

(2019) Wei Xie et al.   OncoImmunology

Crizotinib-induced immunogenic cell death in non-small cell lung cancer

(2019) Peng Liu et al.   Nature Communications

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

(2018) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

(2016) Christina Pfirschke et al.   IMMUNITY

Immunogenic Cell Death in Cancer Therapy

(2012) Guido Kroemer et al.   Annual Review of Immunology